CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

tralokinumab

Last Updated: March 30, 2021
Result type: Reports
Project Number: SR0689-000
Product Line: Reimbursement Review

Generic Name: tralokinumab

Brand Name: TBC

Manufacturer: LEO Pharma Inc.

Therapeutic Area: atopic dermatitis

Indications: Tralokinumab is indicated for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. TRADENAME (tralokinumab) can be used with or without topical corticosteroids.

Manufacturer Requested Reimbursement Criteria1: ​For the treatment of adult patients with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable and who had an adequate trial or be ineligible for each of the following therapies: phototherapy (where available), methotrexate, and cyclosporine.

Submission Type: Initial

Project Status: Pending

Call for patient/clinician input open: March 30, 2021

Call for patient/clinician input closed: May 21, 2021

Anticipated Date: April 28, 2021

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Submit Feedback